| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Phase II Initiated Q1 2021 |
Completion of Phase II Q3 2023 |
|||
| Advanced-stage soild tumors with peritoneal metastases in combination with chemotherapy |
$4B | Phase lb Q2 2022 |
|||||
| Advanced-stage soild tumors with peritoneal metastases stand-alone, + in combination with anti-PD1 |
$4B | Phase I/II Q3 2022 |
|||||
Pipelinemonimono2022-06-11T01:20:34+03:00
